<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The ability of chlormethiazole to protect against ischaemic cell damage in a rat model of permanent focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> has been examined </plain></SENT>
<SENT sid="1" pm="."><plain>Chlormethiazole (1 mmol/kg) was administered intraperitoneally either 1 or 3 h after occlusion of the middle cerebral artery with an intraluminal filament </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty four hours after the start of occlusion there was histological evidence for ischaemic damage in both cortex and striatum </plain></SENT>
<SENT sid="3" pm="."><plain>The volume of ischaemic damage in control (saline injected) animals was 310 +/- 25 mm3 (mean +/- <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>; n = 6) </plain></SENT>
<SENT sid="4" pm="."><plain>Chlormethiazole administered 1 h after occlusion reduced this damage by 58% (128 +/- 40 mm3; n = 6; P &lt; 0.01), protection being observed in both brain regions </plain></SENT>
<SENT sid="5" pm="."><plain>The drug was ineffective when given 3 h after occlusion (304 +/- 25 mm3; n = 5) </plain></SENT>
<SENT sid="6" pm="."><plain>Chlormethiazole had no effect on body temperature, mean arterial blood pressure, blood pH, pO2 or pCO2, but did induce mild <z:hpo ids='HP_0001662'>bradycardia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Chlormethiazole therefore appears to be an effective neuroprotective agent in this model of permanent <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, complementing previous data on the efficacy of this drug in other focal and global models of <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
</text></document>